Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Eurizon Capital SGR opened a new position in Bristol Myers Squibb during the fourth quarter, buying 1,526,318 shares worth about $82.4 million.
• Institutional ownership remains heavy, with hedge funds and other investors holding 76.41% of the company’s stock. Several large firms, including Vanguard and Geode Capital, also increased their stakes.
• Analysts are mixed on BMY: the consensus rating is Hold with an average price target of $61.31, while Bristol Myers also reported a recent quarterly earnings beat and continues to highlight encouraging pipeline updates in oncology.

Eurizon Capital SGR S.p.A. acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,526,318 shares of the biopharmaceutical company's stock, valued at approximately $82,354,000. Eurizon Capital SGR S.p.A. owned 0.07% of Bristol Myers Squibb at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after buying an additional 2,743,759 shares during the period. State Street Corp lifted its position in shares of Bristol Myers Squibb by 2.0% during the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock worth $4,356,445,000 after purchasing an additional 1,855,238 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Bristol Myers Squibb by 11.5% during the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock worth $818,105,000 after purchasing an additional 1,873,618 shares in the last quarter. Finally, Pzena Investment Management LLC lifted its position in shares of Bristol Myers Squibb by 20.4% during the fourth quarter. Pzena Investment Management LLC now owns 17,943,503 shares of the biopharmaceutical company's stock worth $967,873,000 after purchasing an additional 3,041,899 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of several research reports. Cantor Fitzgerald increased their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 8th. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a "hold" rating in a research report on Tuesday, March 17th. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price target on the stock. Finally, Morgan Stanley reissued an "underweight" rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $61.31.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMS reported encouraging late-stage data for mezigdomide, saying the experimental CELMoD cut the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma. That is the kind of readout investors watch for because it strengthens the case for a future commercial opportunity. Article Title
• Positive Sentiment: The company also highlighted mezigdomide data in a business update, reinforcing optimism around its broader oncology pipeline and suggesting Celgene-derived assets continue to support long-term growth prospects. Article Title
• Positive Sentiment: Bristol Myers Squibb said it is backing a new cell-therapy combination in an early gastrointestinal cancer trial, which adds another potential pipeline catalyst and underscores continued investment in high-value cancer programs. Article Title
• Positive Sentiment: BMS also announced a strategic partnership with Anthropic to use Claude across research, clinical development, manufacturing, commercial, and corporate functions, a move that could improve productivity and speed decision-making over time. Article Title

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $57.17 on Friday. The firm has a market capitalization of $116.75 billion, a P/E ratio of 16.06, a P/E/G ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm's 50 day moving average is $58.32 and its two-hundred day moving average is $56.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio is currently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.